Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Novel lawsone-containing ruthenium(II) complexes: Synthesis, characterization and anticancer activity on 2D and 3D spheroid models of prostate cancer cells

Full text
Author(s):
De Grandis, Rone Aparecido [1] ; da Silva dos Santos, Patrick Wellington [2] ; de Oliveira, Katia Mara [3] ; Tomazela Machado, Ana Rita [2] ; Aissa, Alexandre Ferro [2] ; Batista, Alzir Azevedo [3] ; Greggi Antunes, Lusania Maria [2] ; Pavan, Fernando Rogerio [1]
Total Authors: 8
Affiliation:
[1] Sao Paulo State Univ, Sch Pharmaceut Sci, BR-14800903 Araraquara, SP - Brazil
[2] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, BR-14040903 Ribeirao Preto, SP - Brazil
[3] Univ Fed Sao Carlos, Dept Chem, BR-13561901 Sao Carlos, SP - Brazil
Total Affiliations: 3
Document type: Journal article
Source: BIOORGANIC CHEMISTRY; v. 85, p. 455-468, APR 2019.
Web of Science Citations: 0
Abstract

This study describes a series of newly synthesized phosphine/diimine ruthenium complexes containing the lawsone as bioligand with enhanced cytotoxicity against different cancer cells, and apoptosis induction in prostatic cancer cells DU-145. The complexes {[}Ru(law)(N-N)(2)]PF6 where N-N is 2,2'-bipyridine (1) or 1,10-phenanthroline (2) and {[}Ru(law)(dppm)(N-N)]PF6, where dppm means bis(diphenylphosphino)methane, N-N is 2,2'-bipyridine (3) or 1,10-phenanthroline (4), and law is lawsone, were synthesized and fully characterized by elemental analysis, molar conductivity, NMR, UV-vis, IR spectroscopies and cyclic voltammetry. The interaction of the complexes (1-4) with DNA was evaluated by circular dichroism, gel electrophoresis, and fluorescence, and the complexes presented interactions by the minor grooves DNA. The phosphinic series of complexes exhibited a remarkably broad spectrum of anticancer activity with approximately 34-fold higher than cisplatin and 5-fold higher than doxorubicin, inhibiting the growth of 3D tumor spheroids and the ability to retain the colony survival of DU-145 cells. Also, the complex (4) inhibits DU-145 cell adhesion and migration potential indicating antimetastatic properties. The mechanism of its anticancer activity was found to be related to increased reactive oxygen species (ROS) generation, increased the BAX/BCL-2 ratio and subsequent apoptosis induction. Overall, these findings suggested that the complex (4) could be a promising candidate for further evaluation as a chemotherapeutic agent in the prostate cancer treatment. (AU)

FAPESP's process: 16/16312-0 - Cytotoxicity and mechanism of action of ruthenium complexes containing natural products or derivatives
Grantee:Alzir Azevedo Batista
Support type: Regular Research Grants
FAPESP's process: 16/22429-7 - Toxicogenetics evaluation and study of antiproliferative response mechanisms of ruthenium-based metallodrugs containing naphthoquinones ligands in tumor cells growing in conventional and 3D systems
Grantee:Rone Aparecido de Grandis
Support type: Scholarships in Brazil - Doctorate
FAPESP's process: 18/00163-0 - Development and search of new antimicrobials against tuberculosis: from screening to pre-clinical studies in vivo
Grantee:Fernando Rogério Pavan
Support type: Regular Research Grants